Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics to present a poster at ASGCT on the Development of a mRNA-Engineered iPSC Line, via Targeted Insertion of HLA-E at the B2M Locus
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (Eterna or the Company), a life science company committed to realizing the potential of mRNA cell...
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (Eterna or the Company), a life science company committed to realizing the potential of mRNA cell...
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (Eterna or the Company), a life science company committed to realizing the potential of mRNA cell...
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (Eterna or the Company), a life science company committed to realizing the potential of mRNA cell...
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics